Core Viewpoint - The company reported a significant decline in its main business revenue for the first half of 2025, with a total revenue of 960.85 million yuan, representing a decrease of 149.52 million yuan or 13.47% compared to the previous year [10][12]. Financial Data - The main business revenue for the reporting period was 960.85 million yuan, down from the previous year's figure [10]. - The pharmaceutical manufacturing segment saw a revenue decline of 119.97 million yuan, a decrease of 17.88% [10]. - The pharmaceutical commercial segment experienced a revenue drop of 29.55 million yuan, a decrease of 6.73% [10]. - The total sales revenue from major products was 523.22 million yuan, reflecting a decrease of 123.81 million yuan or 19.14% year-on-year [11]. Regional Performance - Sales revenue by region showed varied performance, with North China experiencing a slight increase of 4.32%, while other regions faced declines: South China down 35.01%, Southwest down 21.33%, Northwest down 20.25%, Northeast down 17.89%, Central China down 12.58%, and East China down 9.53% [12]. - Exports saw a dramatic decline of 88.15% compared to the same period last year [12]. Shareholder Activity - Zhang Ya, a significant shareholder, reduced her holdings by 10,304,700 shares, which accounted for 1.93% of the company's total share capital [3][4].